Management of mild cognitive impairment (MCI): The need for national and international guidelines

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F20%3A10410847" target="_blank" >RIV/00216208:11130/20:10410847 - isvavai.cz</a>

Alternative codes found

RIV/00159816:_____/20:00073471 RIV/00064203:_____/20:10410847

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=g3R34SCaQa" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=g3R34SCaQa</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/15622975.2019.1696473" target="_blank" >10.1080/15622975.2019.1696473</a>

Result language

angličtina

Original language name

Management of mild cognitive impairment (MCI): The need for national and international guidelines

Original language description

Objectives: To review available evidence of pharmacological and non-pharmacological treatment for MCI and analyse information and limitations in national and international guidelines. Methods: Experts from several European countries conducted a qualitative review of the literature on MCI and treatments for MCI, as well as respective chapters in national and international guidelines on dementia/MCI. Psychotherapeutic/psychosocial treatments were excluded from the review. Results: Consensus diagnostic criteria for MCI are available, making early recognition and accurate classification of MCI subtypes possible. MCI can be identified in a primary care setting. Further corroboration and differential diagnosis should be done at specialist level. Mixed pathologies are the rule in MCI, thus a multi-target treatment approach is a rational strategy. Promising evidence has been generated for multi-domain interventions. Limited evidence is available for different pharmacological classes that have been investigated in MCI clinical trials (e.g. acetylcholinesterase inhibitors). EGb 761 (R) improved symptoms in some clinical trials; it is the only pharmacological treatment recommended in existing guidelines for the symptomatic treatment of MCI. Conclusions: MCI is recognised as an important treatment target and some recent national guidelines have considered symptomatic treatment recommendations for MCI. However, more needs to be done, especially at an international level.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

World Journal of Biological Psychiatry

ISSN

1562-2975

e-ISSN

—

Volume of the periodical

21

Issue of the periodical within the volume

8

Country of publishing house

GB - UNITED KINGDOM

Number of pages

16

Pages from-to

579-594

UT code for WoS article

000512861800001

EID of the result in the Scopus database

2-s2.0-85079193871